Ophthalmology Division
Research
Clinical Trials
Currently Recruiting
All studies have been approved by the Institutional Review Board.
- RIDE Study
A Phase III, Double-Masked, Multicenter, Randomized, Sham-Injection Controlled Study of the Efficacy and Safety of Ranibizumab (Lucentis) Injection in Subjects with Clinically Significant Macular Edema with Center involvement Secondary to Diabetes Mellitus
Objective: This clinical trial study (duration of 36 months) will evaluate the safety and effectiveness of ranibizumab for diabetic macular edema, the major cause of significant visual loss in diabetics.
Sponsor: Genentech, Inc.
Principal Investigators: Arup Das, MD, PhD; Bob Avery, MD, PhD
Clinical Coordinator: Sheila Nemeth, COMT
Contact: (505)-272-3856 - READ-2 Study
Ranibizumab (Lucentis) for Edema of the Macula in Diabetes: a Phase II Study
Objective: This is a multi-center clinical trial studying the effectivity and safety of ranibizumab and/or laser treatment with only laser treatment for diabetic macular edema.
Sponsor: Juvenile Diabetes Research Foundation and Genentech, Inc.
P.I.: Arup Das, MD, PhD
Clinical Coordinator: Sheila Nemeth, COMT
Contact: (505)-272-3856 - Violet Study
A 24-week, Randomized, Double-blind, Placebo Controlled, Safety and Efficacy Trial of Flibanserin 50 and 100 Milligrams Each Evening in Premenopausal Women with Hypoactive Sexual Desire Disorder
Objective: The purpose of this study is to document the safety profile and to establish the effectiveness of flibanserin in producing a clinically meaningful therapeutic response for premenopausal women with Hypoactive Sexual Desire Disorder (HSDD).
Sponsor: Boehringer Ingelheim
Principal Investigator : Maxine Dorin, M.D
Investigator: Roy Sanchez, O.D.
Clinical Coordinator: Lorraine Griner
Contact: (505)-272-4051 - Novartis FTY720 Study
A 24-month double-blind, randomized, multicenter, placebo-controlled, parallel-group study comparing the efficacy and safety of 0.5 mg and 1.25 mg fingolimod (FTY720) administered orally once daily versus placebo in patients with relapsing-remitting multiple sclerosis (MS)
Objective: A two year study will provide efficacy, safety and tolerability data of fingolimod (FTY720-oral drug) compared with placebo in patients with relapsing remitting multiple sclerosis.) Fingolimod has been previously associated with a two-fold increase in the risk of macular edema in renal transplant patients. Although there have been no confirmed cases of macular edema in MS, careful ophthalmic monitoring is being implemented in this study for early detection of this event.
Sponsor: Novartis
P.I.: Corey Ford, M.D.
Investigator: Thomas Carlow, M.D.
Clinical Coordinator: Lori Bachert
Contact: (505)-272-8905 - Lupus Study
Libman-Sacks Endocarditis as a Cause of Neuropsychiatric Systemic Lupus Erythematosus
Objective: A four-year study will examine if microthrombi in patients with valvular heart diseases cause the cerebral lesions in neuropsychiatric systemic lupus erythematosus. The study will include examination of retinas of these patients for retinal microemboli and retinal atherosclerosis lesions.
Sponsor: National Heart, Lung and Blood Institute (NIH)
P.I.: Carlos Roldan, M.D.
Investigator: Arlene Bagga, M.D.
Clinical Coordinator: Janeen Sharrar, R.N.
Contact: (505)-272-4253 - EDIC Study
Epidemiology of Diabetes Interventions and Complications
Objective: This is the national long-term follow-up study of the same group studied in the Diabetes Control and Complications Trial (DCCT). The volunteers in this study have type1 diabetes. EDIC has followed these participants to find out if intensive therapy provides risk reduction for retinopathy, nephropathy and neuropathy. EDIC is now in its 13th year of monitoring the development of complication outcomesin order to see the impact of well-controlled type1 diabetes.
Sponsor: National Institutes of Health (NIH); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
P.I.: David Schade, M.D.
Clinical Coordinator: Janene Canady, RN
Contact: (505)-272-6949 - DPPOS Study
Diabetes Prevention Program Outcomes Study
Objective: A multi-center contolled clinical trial that examines the efficacy of an intensive lifestyle intervention or metformin to prevent or delay the development of Type 2 diabetes in a population selected to be high-risk due to the presence of impaired glucose tolerance.
Sponsor: National Institutes of Health (NIH)
P.I.: David Schade, MD
Clinical Coordinator: Penny Hyde, RN
Contact: 505-272-1200
Basic Science Research
Arup Das, M.D., Ph.D.
Publications
Dusanka Deretic, Ph. D.
Publications
Research
Paul McGuire, Ph.D.
Publications
Basic Science Research Lab
Paul McGuire, Ph.D.
Anupam Basu, Ph.D.
Ramprasad Srinivasan, PhD
Joann Maestas
(These should link to InfoEd pages
... info on adding them ...)